AstraZeneca eyes new cancer treatments with Fusion deal
AstraZeneca said today it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals for about $2 billion in cash as the Anglo-Swedish drugmaker bets on next-generation cancer treatments.
Business
• 19 Mar 24
